Upadacitinib Maintenance Therapy in Pediatric Ulcerative Colitis: 52-Week Multicenter Study From the Porto Group of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition
Clinical Gastroenterology and Hepatology · 2026-10 · 24 (10) · 2762-2772
DOI: 10.1016/j.cgh.2026.02.012 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-10. Verfasst von Anat Yerushalmy-Feler und 39 weiteren Autor:innen. Beteiligte Einrichtung: Tel Aviv Sourasky Medical Center, Pediatric Gastroenterology Institute, "Dana-Dwek" Children's Hospital, Tel Aviv, Israel; The Gray Faculty of Medica…. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Heterocyclic Compounds, 3-Ring, Maintenance Chemotherapy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND & AIMS: Data on upadacitinib therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBD-U) are scarce. We aimed to evaluate the effectiveness and safety of upadacitinib as a maintenance therapy in pediatric UC. METHODS: Children treated with upadacitinib for maintenance of remission of active UC or IBD-U from 35 centers affiliated with the Porto group of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) were enrolled in this retrospective study. Data on demographic, clinical, laboratory, endoscopic, imaging, and adverse events (AEs) were recorded over 52 weeks of follow-up. RESULTS: A total of 105 children were included (95 with UC and 10 with IBD-U; mean age, 14.6 ± 3.3 years). Prior to upadacitinib, 103 of 105 children (98%) were treated with biologic therapies and 79 (75%) with ≥2 biologics. Clinical remission and corticosteroid-free clinical remission (CFR) were observed after 8 weeks in 61 (58%) and 53 (51%) children, respectively. By week 52, 75 children (71%) achieved clinical remission and 73 (70%) achieved CFR. Sustained CFR was recorded in 63 children (60%). CFR with normal C-reactive protein was observed in 56% of children, and CFR with fecal calprotectin levels
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tel Aviv Sourasky Medical Center, Pediatric Gastroenterology Institute, "Dana-Dwek" Children's Hospital, Tel Aviv, Israel; The Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Division of Pediatric Gastroenterology, Susan and Leonard Feinstein IBD Clinical Center, Icahn School of Medicine at Mount Sinai, New York, New York.
- University of Washington Medical School, Seattle, Washington; Division of Pediatric Gastroenterology, Seattle Children's Hospital, Inflammatory Bowel Disease Center, University of Washington, Seattle, Washington.
- Department of Paediatrics, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
- Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
- Department of Pediatrics, Gastroenterology and Nutrition, University Children's Hospital in Cracow, Jagiellonian University Medical College, Cracow, Poland.
Zitieren
APA
Yerushalmy-Feler, A., Spencer, E. A., Dubinsky, M. C., Suskind, D. L., Mitrova, K., Hradsky, O., Conrad, M. A., Kelsen, J. R., Sladek, M., Yeh, P. J., Tzivinikos, C., Henderson, P., Wlazlo, M., Hackl, L., Shouval, D. S., Mouratidou, N., Bramuzzo, M., Urlep, D., Olbjørn, C., …, & Cohen, S. (2026). Upadacitinib Maintenance Therapy in Pediatric Ulcerative Colitis: 52-Week Multicenter Study From the Porto Group of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition. Clinical Gastroenterology and Hepatology, 24(10), 2762-2772. https://doi.org/10.1016/j.cgh.2026.02.012
Vancouver
Yerushalmy-Feler A, Spencer EA, Dubinsky MC, Suskind DL, Mitrova K, Hradsky O, et al. Upadacitinib Maintenance Therapy in Pediatric Ulcerative Colitis: 52-Week Multicenter Study From the Porto Group of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition. Clinical Gastroenterology and Hepatology. 2026;24(10):2762-2772. doi:10.1016/j.cgh.2026.02.012
BibTeX
@article{YerushalmyFeler2026,
author = {Yerushalmy-Feler, Anat and Spencer, Elizabeth A and Dubinsky, Marla C and Suskind, David L and Mitrova, Katarina and Hradsky, Ondrej and Conrad, Máire A and Kelsen, Judith R and Sladek, Malgorzata and Yeh, Pai-Jui and Tzivinikos, Christos and Henderson, Paul and Wlazlo, Magdalena and Hackl, Lukas and Shouval, Dror S and Mouratidou, Natalia and Bramuzzo, Matteo and Urlep, Darja and Olbjørn, Christine and Mancuso, Giulia and Schneider, Anna-Maria and Pujol-Muncunill, Gemma and Yogev, Dotan and Kang, Ben and Gasparetto, Marco and Rungø, Christine and Romano, Claudio and Martinelli, Massimo and Kolho, Kaija-Leena and Hojsak, Iva and Norsa, Lorenzo and Rinawi, Firas and Sansotta, Naire and Rimon, Ramit Magen and Granot, Maya and Scarallo, Luca and Trindade, Eunice and Rodríguez-Belvís, Marta Velasco and Turner, Dan and Cohen, Shlomi},
title = {Upadacitinib Maintenance Therapy in Pediatric Ulcerative Colitis: 52-Week Multicenter Study From the Porto Group of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
volume = {24},
number = {10},
pages = {2762--2772},
doi = {10.1016/j.cgh.2026.02.012}
}
EUVIMED